Deficit schizophrenia: An overview of clinical, biological and treatment aspects

European Psychiatry

Volumn 24, Issue 8, 2009, Pages 493-500

  Galderisi, S ^a   Maj, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Deficit Schizophrenia; Genetic; Heterogeneity; MRI; Nondeficit schizophrenia; Schizophrenia subtypes

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CATECHOL METHYLTRANSFERASE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANAMNESIS; BRAIN ELECTROPHYSIOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DEFICIT SCHIZOPHRENIA; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; LONG TERM CARE; LOW DRUG DOSE; NEGATIVE SYNDROME; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; POSITIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCHIZOPHRENIA; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 70649085154     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.03.001     Document Type: Short Survey

References (95)

1. Amador X.F., Kirkpatrick B., Buchanan R.W., Carpenter W.T., Marcinko L., and Yale S.A. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 156 (1999) 637-639
2. Andreasen N.C., and Olsen S. Negative versus positive schizophrenia. Arch Gen Psychiatry 39 (1982) 789-794
3. Arango C., Kirkpatrick B., and Buchanan R.W. Neurological signs and the heterogeneity of schizophrenia. Am J Psychiatry 157 (2000) 560-565
4. Arndt S., Andreasen N.C., Flaum M., Miller D., and Nopoulos P. A longitudinal study of symptoms dimensions in schizophrenia: prediction and patterns of changes. Arch Gen Psychiatry 52 (1995) 352-360
5. Bakker S.C., Hoogendoorn M.L., Hendriks J., Verzijlbergen K., Caron S., Verduijn W., et al. The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6 (2007) 113-119
6. Boyer P., Lecrubier Y., Puech A.J., Dewailly J., and Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166 (1995) 68-72
7. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151 (1994) 20-26
8. Bryson G., Whelahan H.A., and Bell M. Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res 102 (2001) 29-37
9. Bucci P., Mucci A., Merlotti E., Volpe U., and Galderisi S. Induced gamma activity and event-related coherence in schizophrenia. Clin EEG Neurosci 38 (2007) 97-104
10. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., and Carpenter Jr. W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155 (1998) 751-760
11. Buchanan R.W., Breier A., Kirkpatrick B., Elkashef A., Munson R.C., Gellad F., et al. Structural abnormalities in deficit vs non-deficit schizophrenia. Am J Psychiatry 150 (1993) 59-65
12. Buchanan R.W., and Heinrichs D.W. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 27 (1988) 335-350
13. Buchanan R.W., Kirkpatrick B., Heinrichs D.W., and Carpenter Jr. W.T. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 147 (1990) 290-294
14. Buchanan R.W., Strauss M.E., Kirkpatrick B., Holstein C., Breier A., and Carpenter Jr. W.T. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 51 (1994) 804-811
15. Cannon-Spoor H.E., Potkin S.G., and Wyatt R.J. Measurement of premorbid adjustment in schizophrenia. Schizophr Bull 8 (1982) 470-484
16. Carpenter Jr. W.T., Heinrichs D.W., and Wagman A.M.I. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 145 (1988) 578-583
17. Cohen A.S., Saperstein A.M., Gold J.M., Kirkpatrick B., Carpenter Jr. W.T., and Buchanan R.W. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 33 (2007) 1201-1212
18. Crow T.J. The two-syndrome concept: origins and current status. Schizophr Bull 11 (1985) 471-486
19. Danion J.M., Rein W., Fleurot O., and Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 156 (1999) 610-616
20. Davies G.W.J., Chant D., Torrey E.F., and McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 29 (2003) 587-593
21. Delamillieure P., Fernandez J., Constans J.M., Brazo P., Benali K., Abadie P., et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatry 157 (2000) 641-643
22. Dickerson F., Kirkpatrick B., Boronow J., Stallings C., Origoni A., and Yolken R. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 32 (2006) 396-400
23. Dollfus S., Brazo P., Langlois S., Gourevitch R., Dassa D., Besse F., et al. Month of birth in deficit and non-deficit schizophrenic patients. Eur Psychiatry 14 (1999) 349-351
24. Dollfus S., Germain-Robin S., Chabot B., Brazo P., Delamillieure P., Langlois S., et al. Family history and obstetric complications in deficit and non-deficit schizophrenia: preliminary results. Eur Psychiatry 13 (1998) 270-272
25. Fenton W.S., McGlashan T.H., Victor B.J., and Blyler C.R. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 154 (1997) 199-204
26. Fenton W.S., and McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 151 (1994) 351-356
27. Galderisi S., Maj M., Kirkpatrick B., Piccardi P., Mucci A., Invernizzi G., et al. Catechol-O-methyltransferase Val 158 Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52 (2005) 83-89
28. Galderisi S., Maj M., Kirkpatrick B., Piccardi P., Mucci A., Invernizzi G., et al. COMT Val (158) Met and BDNF C (270) T polymorphisms in schizophrenia: a case-control study. Schizophr Res 73 (2005) 27-30
29. Galderisi S., Maj M., Mucci A., Cassano G.B., Invernizzi G., Rossi A., et al. Historical, psychopathological, neurological and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 159 (2002) 983-990
30. Galderisi S., Mucci A., Mignone M.L., Bucci P., and Maj M. Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. Int J Psychophysiol 34 (1999) 293-301
31. Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, et al. Patterns of structural MRI abnormalities in deficit and non-deficit schizophrenia. Schizophr Bull 2008; 34:393-401.
32. Goetz R.R., Corcoran C., Yale S., Stanford A.D., Kimhy D., Amador X., et al. Validity of a 'proxy' for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res 93 (2007) 169-177
33. Gonul A.S., Kula M., Esel E., Tutus A., and Sofuogluc S. A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res Neuroimaging 123 (2003) 199-205
34. Gur R.E., Mozley P.D., Shtasel D.L., et al. Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 151 (1994) 343-350
35. Heckers S., Goff D., Schacter D.L., Savage C.R., Fischman A.J., Alpert N.M., et al. Functional imaging of memory retrieval in deficit vs non-deficit schizophrenia. Arch Gen Psychiatry 56 (1999) 1117-1123
36. Hong L.E., Avila M.T., Adami H., Elliot A., and Thaker G.K. Components of the smooth pursuit function in deficit and non-deficit schizophrenia. Schizophr Res 63 (2003) 39-48
37. Johnstone E.C., Owen D.G., Frith C.D., and Crow T.J. The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry 150 (1987) 60-64
38. Kay S.R., and Singh M.M. The positive-negative distinction in drug-free schizophrenic patients. Stability, response to neuroleptics, and prognostic significance. Arch Gen Psychiatry 46 (1989) 711-718
39. Kimhy D., Yale S., Goetz R.R., McFarr L.M., and Malaspina D. The factorial structure of the Schedule for the Deficit Syndrome in schizophrenia. Schizophr Bull 32 (2006) 274-278
40. Kirkpatrick B., Amador X.A., Yale S.A., Bustillo J.R., Buchanan R.W., and Tohen M. The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res 20 (1996) 79-90
41. Kirkpatrick B., Amador X.S., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T., et al. The deficit syndrome in the DSM-IV Field Trial. I: alcohol and other drug abuse. Schizophr Res 20 (1996) 69-77
42. Kirkpatrick B., Buchanan R.W., Breier A., and Carpenter Jr. W.T. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 47 (1993) 47-56
43. Kirkpatrick B., Buchanan R.W., Breier A., and Carpenter Jr. W.T. Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 182 (1994) 452-455
44. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., and Carpenter Jr. W.T. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30 (1989) 119-124
45. Kirkpatrick B., Buchanan R.W., Ross D.E., and Carpenter Jr. W.T. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58 (2001) 165-171
46. Kirkpatrick B., and Buchanan R.W. Anhedonia and the deficit syndrome of schizophrenia. Psychiatry Res 31 (1990) 25-30
47. Kirkpatrick B., Castle D., Murray R.M., and Carpenter W.T. Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull 26 (2000) 233-242
48. Kirkpatrick B., Conley R.C., Kakoyannis A., Reep R.L., and Roberts R.C. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse 34 (1999) 95-102
49. Kirkpatrick B., Fenton W.S., Carpenter Jr. W.T., and Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32 (2006) 214-219
50. Kirkpatrick B., Herrera Castanedo S., and Vazquez-Barquero J.L. Summer birth and deficit schizophrenia: Cantabria, Spain. J Nerv Ment Dis 190 (2002) 526-532
51. Kirkpatrick B., Kopelowicz A., Buchanan R.W., and Carpenter Jr. W.T. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22 (2000) 303-310
52. Kirkpatrick B., Messias N.C., Conley R.R., and Roberts R.C. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and non-deficit schizophrenia. J Nerv Ment Dis 191 (2003) 563-567
53. Kirkpatrick B., Ram R., and Bromet E. The deficit syndrome in the Suffolk County Mental Health Project. Schizophr Res 22 (1996) 119-126
54. Kirkpatrick B., Ross D.E., Walsh D., Karkowski L., and Kendler K.S. Family characteristics of deficit and non-deficit schizophrenia in the Roscommon Family Study. Schizophr Res 45 (2000) 57-64
55. Kirkpatrick B., Tek C., Allardyce J., Morrison G., and McCreadie R.G. Summer birth and deficit schizophrenia in Dumfries and Galloway, Southwestern Scotland. Am J Psychiatry 150 (2002) 1382-1387
56. Kopelowicz A., Zarate R., Tripodis K., Gonzalez V., and Mintz J. Differential efficacy of olanzapine for deficit and non-deficit negative symptoms in schizophrenia. Am J Psychiatry 157 (2000) 987-993
57. Kraepelin E. Psychiatrie: ein lehrbuch fur studierende und artze. 5. Auflage (1896), A. Abel, Leipzig
58. Lahti A.C., Holcomb H.H., Medoff D.R., Weiler M.A., Tamminga C.A., and Carpenter Jr. W.T. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 158 (2001) 1797-1808
59. Lecrubier Y., Quintin P., Bouhassira M., Perrin E., and Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 114 (2006) 319-327
60. Lee K.H., Williams L.M., Loughland C.M., Davidson D.J., and Gordon E. Syndromes of schizophrenia and smooth-pursuit eye movement dysfunction. Psychiatry Res 101 (2001) 11-21
61. Leucht S., Pitschel-Walz G., Engel R.R., and Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159 (2002) 180-190
62. Liddle P.F., and Barnes T.R.E. Syndromes of chronic schizophrenia. Br J Psychiatry 157 (1990) 558-561
63. Lindenmayer J.P., Khan A., Iskander A., Abad M.T., and Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 68 (2007) 368-379
64. Loo H., Poirier-Littre M.F., Theron M., Rein W., and Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170 (1997) 18-22
65. Malaspina D., Goetz R.R., Yale S., Berman A., Friedman J.H., and Tremeau F. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. Am J Psychiatry 157 (2000) 994-1003
66. McGlashan T.H., and Fenton W.S. The positive-negative distinction in schizophrenia: review of natural history validators. Arch Gen Psychiatry 49 (1992) 63-72
67. Messias E., Kirkpatrick B., Bromet E., Ross D., Buchanan R.W., Carpenter Jr. W.T., et al. Summer birth and deficit schizophrenia. a pooled analysis from 6 countries. Arch Gen Psychiatry 61 (2004) 985-989
68. Messias E., and Kirkpatrick B. Summer birth and deficit schizophrenia in the Epidemiologic Catchment Area study. J Nerv Ment Dis 189 (2001) 608-612
69. Minoretti P., Politi P., Coen E., Di Vito C., Bertona M., Bianchi M., et al. The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397 (2006) 159-163
70. Mucci A., Galderisi S., Kirkpatrick B., Bucci P., Volpe U., Merlotti E., et al. Double dissociation of N1 and P3 abnormalities in deficit and non-deficit schizophrenia. Schizophr Res 92 (2007) 252-261
71. Murphy B.P., Chung Y.-C., Park T.-W., and McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 88 (2006) 5-25
72. Nakaya M., and Ohmori K. A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res 158 (2008) 256-259
73. Nkam I., Thibaut F., Denise P., Van Der Elst A., Ségard L., Brazo P., et al. Saccadic and smooth-pursuit eye movements in deficit and non-deficit schizophrenia. Schizophr Res 48 (2001) 145-153
74. Paillère-Martinot M.-L., Lecrubier Y., Martinot J.L., and Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152 (1995) 130-133
75. Peralta V., de Leon J., and Cuesta M.J. Are there more than two syndromes in schizophrenia? A critique of the positive-negative dichotomy. Br J Psychiatry 161 (1992) 335-343
76. Pogue-Geile M.F., and Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 11 (1985) 427-439
77. Polgár P, Farkas M, Nagy O, Kelemen O, Réthelyi J, Bitter I, et al. How to find the way out from four rooms? The learning of "chaining" associations may shed light on the neuropsychology of the deficit syndrome of schizophrenia. Schizophr Res. 2008;99:200-7.
78. Quarantelli M., Larobina M., Volpe U., Amati G., Tedeschi E., Ciarmiello A., et al. Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and non-deficit schizophrenia. NeuroImage 17 (2002) 373-384
79. Rey E.R., Bailer J., Bräuer W., Händel M., Laubenstein D., and Stein A. Stability trends and longitudinal correlations of negative and positive syndromes within a three-year follow-up of initially hospitalized schizophrenics. Acta Psychiatr Scand 90 (1994) 405-412
80. Rosenheck R., Dunn L., Peszke M., Cramer J., Xu W., Thomas J., et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 156 (1999) 88-93
81. Ross D.E., Kirkpatrick B., Karkowski L.M., Straub R.E., MacLean C.J., O'Neill F.A., et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry 157 (2000) 1071-1076
82. Ross D.E., Thaker G.K., Buchnan R.W., Kirkpatrick B., Lahti A.C., Medoff D., et al. Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients. Am J Psychiatry 153 (1997) 1158-1165
83. Sigmundsson T., Suckling J., Maier M., Williams S., Bullmore E., Greenwood K., et al. Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158 (2001) 234-243
84. Smith R.C., Kadewari R.P., Rosenberger J.R., and Bhattacharyya A. Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. Schizophr Bull 25 (1999) 813-825
85. Strauss J.S., and Carpenter W.T. The prediction of outcome in schizophrenia. I: characteristics of outcome. Arch Gen Psychiatry 27 (1972) 739-746
86. Tamminga C.A., Thaker G.K., Buchanan R.W., Gao X., Shirakawa O., Buchanan R., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49 (1992) 522-530
87. Tandon R., DeQuardo J.R., Taylor S.F., et al. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45 (2000) 191-201
88. Tek C., Kirkpatrick B., and Buchanan R.W. A five-year follow-up study of deficit and non-deficit schizophrenia. Schizophr Res 49 (2001) 253-260
89. Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154 (1997) 466-474
90. Turetsky B., Cowell P.E., Gur R.C., Grossman R.I., Shtasel D.L., and Gur R.E. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry 52 (1995) 1061-1070
91. Turetsky B.I., Colbath E.A., and Gur R.E. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol Psychiatry 43 (1998) 84-96
92. Vaiva G., Cottencin O., Llorca P.M., Devos P., Dupont S., Mazas O., et al. Regional cerebral blood flow in deficit/non-deficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 481-485
93. Vaiva G., Thomas P., Llorca P.M., Dupont S., Cottencin O., Devos P., et al. SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res 115 (2002) 37-48
94. Waltrip R.W., Buchanan R.W., Carpenter Jr. W.T., Kirkpatrick B., Summerfelt A., Breier A., et al. Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res 23 (1997) 253-258
95. Wonodi I., Mitchell B.D., Stine O.C., Hong L.E., Elliott A., Kirkpatrick B., et al. Lack of association between COMT gene and deficit/non-deficit schizophrenia. Behav Brain Funct 2 (2006) 42